Desloratadine Teva 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/962/ 
Periodic Safety Update EU Single assessment - 
24/03/2022 
30/05/2022 
SmPC and PL 
Please refer to Aerius-Azomyr-Neoclarityn-Desloratadine 
202107 
desloratadine 
Teva-Dasselta-Desloratadine Actavis-Desloratadine 
ratiopharm-EMEA/H/C/PSUSA/00000962/202107 EPAR: 
Scientific conclusions and grounds recommending the 
variation to the terms of the marketing authorisation 
IAIN/0028 
B.II.a.1.a - Change or addition of imprints, bossing 
26/07/2021 
30/05/2022 
SmPC, 
or other markings including replacement, or addition 
Labelling and 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
PL 
IA/0027 
A.7 - Administrative change - Deletion of 
10/02/2021 
30/04/2021 
Annex II and 
manufacturing sites 
N/0026 
Minor change in labelling or package leaflet not 
23/06/2020 
30/04/2021 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
IB/0025 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/04/2020 
30/04/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
IB/0023/G 
This was an application for a group of variations. 
13/02/2020 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.c.z - Container closure system of the AS - Other 
variation 
B.III.2.z - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Other 
variation 
IA/0024 
B.III.2.z - Change to comply with Ph. Eur. or with a 
16/01/2020 
n/a 
national pharmacopoeia of a Member State - Other 
Page 2/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
variation 
N/0022 
Minor change in labelling or package leaflet not 
24/04/2019 
30/04/2021 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0021 
B.II.b.5.z - Change to in-process tests or limits 
02/07/2018 
n/a 
applied during the manufacture of the finished 
product - Other variation 
N/0020 
Minor change in labelling or package leaflet not 
13/03/2018 
12/12/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0018/G 
This was an application for a group of variations. 
07/03/2018 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.4.b - Change to in-process tests or limits 
applied during the manufacture of the AS - Addition 
of a new in-process test and limits 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
IB/0019 
C.I.z - Changes (Safety/Efficacy) of Human and 
17/01/2018 
12/12/2018 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
N/0017 
Minor change in labelling or package leaflet not 
04/12/2017 
12/12/2018 
connected with the SPC (Art. 61.3 Notification) 
PL 
PL 
PSUSA/962/2
Periodic Safety Update EU Single assessment - 
23/03/2017 
24/05/2017 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01607 
desloratadine 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/962/201607. 
IB/0015/G 
This was an application for a group of variations. 
07/12/2016 
n/a 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
variation 
B.I.b.z - Change in control of the AS - Other 
variation 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
Page 5/9 
 
 
 
 
 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
R/0014 
Renewal of the marketing authorisation. 
23/06/2016 
08/08/2016 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Desloratadine Teva in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IA/0013/G 
This was an application for a group of variations. 
04/03/2016 
12/05/2016 
Annex II and 
PL 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/10/2015 
12/05/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
IB/0011 
B.II.e.5.a.2 - Change in pack size of the finished 
28/08/2015 
12/05/2016 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
11/06/2015 
12/05/2016 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/05/2015 
12/05/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IA/0008/G 
This was an application for a group of variations. 
17/02/2015 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
Page 7/9 
 
 
 
 
 
 
 
 
 
 
 
 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
T/0007 
Transfer of Marketing Authorisation from Teva 
03/11/2014 
01/12/2014 
SmPC, 
Pharma B.V. (Utrecht) to Teva B.V. (Haarlem). 
Transfer of Marketing Authorisation 
Labelling and 
PL 
IA/0006/G 
This was an application for a group of variations. 
17/09/2014 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
N/0005 
Minor change in labelling or package leaflet not 
04/06/2014 
01/12/2014 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0004 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/05/2013 
n/a 
Veterinary Medicinal Products - Other variation 
IA/0003 
A.7 - Administrative change - Deletion of 
17/04/2013 
n/a 
manufacturing sites 
N/0002 
Update of the local representatives contact details for 
15/01/2013 
01/12/2014 
PL 
Denmark. 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0001 
C.I.z - Changes (Safety/Efficacy) of Human and 
02/07/2012 
29/10/2012 
SmPC and PL 
Correction of a typographical error in the tablet description 
Veterinary Medicinal Products - Other variation 
in the SmPC and in the PIL for all the product information 
languages and update of the local representatives contact 
details for the United Kingdom, Italy and Ireland. The MAH 
also corrected the pharmaceutical form in the blister 
labelling for the Lithuanian text and amend the INN of 
Desloratadine in the Portuguese text. 
Page 9/9 
 
 
 
 
 
 
 
 
 
